Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Lymphedema 1Locally Advanced Rectal Cancer 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Esophageal Cancer 1Advanced Breast Cancer 1

Interventions

Gemcitabine 13Oxaliplatin 9Capecitabine 6lenvatinib 5apatinib 5Cisplatin 5tislelizumab 4Surgical Procedures, Operative 4Radiofrequency Ablation 4Neoadjuvant Therapy 4Fluorouracil 4toripalimab 3sintilimab 3Radiotherapy 3Leucovorin 3Irinotecan 3regorafenib 2pembrolizumab 2durvalumab 2camrelizumab 2Stents 2Photochemotherapy 2Immunotherapy 2Hepatectomy 2Folfox protocol 2Everolimus 2Drug Therapy 2Cholangiopancreatography, Endoscopic Retrograde 2Blood Specimen Collection 21-phenyl-3,3-dimethyltriazene 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Cholangiocarcinoma × Combined Modality Therapy × Clear all
NCT04413734 2020-06-04

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Zhejiang University

Phase 2 Unknown
120 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡